- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT01915511
Registro dei risultati prospettici della fibrosi polmonare idiopatica e della malattia polmonare interstiziale (IPF/ILD-PRO)
Registro degli esiti prospettici della fibrosi polmonare idiopatica (IPF-PRO) e della malattia polmonare interstiziale fibrosante cronica con esiti prospettici del fenotipo progressivo (IPF-PRO/ILD-PRO)
The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.
Panoramica dello studio
Stato
Descrizione dettagliata
This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Rosalia Blanco
- Numero di telefono: 919-660-0890
- Email: rosalia.blanco@duke.edu
Luoghi di studio
-
-
Alabama
-
Birmingham, Alabama, Stati Uniti, 35294
- Reclutamento
- University of Alabama - Birmingham
-
Investigatore principale:
- Tejaswini Kulkarni, MD
-
Contatto:
- Arnissa Hopson
- Numero di telefono: 205-934-1657
- Email: agoggins@uabmc.edu
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85721
- Reclutamento
- University of Arizona
-
Investigatore principale:
- Sally A Suliman, MD
-
Contatto:
- Daniel Castaneda-Beltran
- Numero di telefono: 602-827-2347
- Email: dcastanedabeltra@arizona.edu
-
-
California
-
Los Angeles, California, Stati Uniti, 90033
- Reclutamento
- University of Southern California
-
Contatto:
- Lynn Fukusima
- Email: Lynn.Fukushima@med.usc.edu
-
Investigatore principale:
- Toby Maher, MD
-
Los Angeles, California, Stati Uniti, 90024
- Reclutamento
- University of California - Los Angeles
-
Investigatore principale:
- John Belperio, MD
-
Contatto:
- Stephanie Roblero
- Numero di telefono: 310-627-2319
- Email: sroblero@mednet.ucla.edu
-
Stanford, California, Stati Uniti, 94305
- Reclutamento
- Stanford University
-
Investigatore principale:
- Rishi Raj, MD
-
Contatto:
- Summer Zhu
- Numero di telefono: 650-724-5424
- Email: szhuye@stanford.edu
-
-
Colorado
-
Aurora, Colorado, Stati Uniti, 80045
- Reclutamento
- University of Colorado
-
Investigatore principale:
- Joyce Lee, MD
-
Contatto:
- Olivia Brohl
- Numero di telefono: 303-724-0641
- Email: Olivia.brohl@cuanschutz.edu
-
-
Connecticut
-
New Haven, Connecticut, Stati Uniti, 06520
- Reclutamento
- Yale University
-
Investigatore principale:
- Mridu Gulati, MD
-
Contatto:
- Maksym Minasyan
- Numero di telefono: 203-785-4177
- Email: maksym.minasyan@yale.edu
-
-
Florida
-
Gainesville, Florida, Stati Uniti, 32610-3175
- Reclutamento
- University of Florida
-
Contatto:
- Lisbetty Lugo
- Email: lisbetty.lugo@medicine.ufl.edu
-
Investigatore principale:
- Diana Gomez Manjarres, MD
-
Tampa, Florida, Stati Uniti, 33606
- Reclutamento
- University of South Florida
-
Investigatore principale:
- Jose D Herazo-Maya, MD
-
Contatto:
- Natasha Brown
- Email: nbrown@tgh.org
-
-
Georgia
-
Atlanta, Georgia, Stati Uniti, 30322
- Reclutamento
- Emory University
-
Contatto:
- Tracy Halabi
- Numero di telefono: 404-712-7458
- Email: tracy.halaby@emory.edu
-
Investigatore principale:
- Srihari Veeraraghavan, MD
-
Austell, Georgia, Stati Uniti, 30106
- Reclutamento
- Piedmont Healthcare
-
Investigatore principale:
- Amy Case, MD
-
Contatto:
- Munachi (Muna) Iwotor
- Numero di telefono: 404-291-9062
- Email: munachi.iwotor@piedmont.org
-
-
Illinois
-
Chicago, Illinois, Stati Uniti, 60637
- Reclutamento
- University of Chicago
-
Investigatore principale:
- Mary Strek, MD
-
Contatto:
- Vanita Patel
- Email: vpatel4@bsd.uchicago.edu
-
Evanston, Illinois, Stati Uniti, 60611
- Reclutamento
- Northwestern University
-
Contatto:
- Phillip Cooper
- Numero di telefono: 312-503-0406
- Email: p-cooper@northwestern.edu
-
Investigatore principale:
- Bradford Bemiss, MD
-
Maywood, Illinois, Stati Uniti, 60153
- Reclutamento
- Loyola University Health System
-
Investigatore principale:
- Daniel Dilling, MD
-
Contatto:
- Sloan White
- Email: swhite29@luc.edu
-
-
Kansas
-
Kansas City, Kansas, Stati Uniti, 66160
- Terminato
- University of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Stati Uniti, 40536
- Reclutamento
- University of Kentucky
-
Investigatore principale:
- Girish Nair, MD
-
Contatto:
- Kai Su
- Numero di telefono: 859-257-4501
- Email: kai.su@uky.edu
-
-
Louisiana
-
New Orleans, Louisiana, Stati Uniti, 70112
- Reclutamento
- Tulane University
-
Investigatore principale:
- Joe Lasky, MD
-
Contatto:
- Sandy Ditta
- Numero di telefono: 504-988-4040
- Email: sditta@tulane.edu
-
-
Michigan
-
Ann Arbor, Michigan, Stati Uniti, 48109
- Attivo, non reclutante
- University of Michigan
-
Detroit, Michigan, Stati Uniti, 48202
- Reclutamento
- Henry Ford Health
-
Contatto:
- Deepti Naidu
- Numero di telefono: 313-916-8732
- Email: dnaidu1@HFHS.ORG
-
Investigatore principale:
- Asif Abdul Hameed, MD
-
-
Minnesota
-
Minneapolis, Minnesota, Stati Uniti, 55455
- Reclutamento
- University of Minnesota
-
Contatto:
- Mandi DeGrote
- Numero di telefono: 612-626-7609
- Email: carl1032@umn.edu
-
Investigatore principale:
- Hyum Kim, MD
-
-
Mississippi
-
Jackson, Mississippi, Stati Uniti, 39216
- Reclutamento
- University of Mississippi Medical Center
-
Investigatore principale:
- Kimberly Dobbs, MD
-
Contatto:
- Leadeashia Brackett
- Numero di telefono: 601-496-7814
- Email: lbrackett@umc.edu
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Reclutamento
- Washington University
-
Investigatore principale:
- Tonya Russell, MD
-
Contatto:
- Mona Noroozi
- Numero di telefono: 314-362-3705
- Email: mnoroozi@wustl.edu
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Reclutamento
- Weill Medical College of Cornell University
-
Investigatore principale:
- Kerri Aronson, MD
-
Contatto:
- Alicia Morris
- Numero di telefono: 646-692-2741
- Email: ajm2017@med.cornell.edu
-
New York, New York, Stati Uniti, 10016
- Attivo, non reclutante
- NYU Medical Center
-
-
North Carolina
-
Chapel Hill, North Carolina, Stati Uniti, 27514
- Reclutamento
- UNC Chapel Hill
-
Investigatore principale:
- Jason Lobo, MD
-
Contatto:
- Jackson Pettee
- Email: Jackson_pettee@med.unc.edu
-
Durham, North Carolina, Stati Uniti, 27705
- Reclutamento
- Duke University
-
Investigatore principale:
- Lake Morrison, MD
-
Contatto:
- Lauren Gray
- Numero di telefono: 919-684-7317
- Email: lauren.gray@duke.edu
-
Greensboro, North Carolina, Stati Uniti, 27403
- Reclutamento
- Pulmonix LLC
-
Investigatore principale:
- Murali Ramaswamy, MD
-
Contatto:
- Mei Zheng
- Numero di telefono: 336-522-8870
- Email: mei.zheng@pulmonix.com
-
Wilmington, North Carolina, Stati Uniti, 28401
- Terminato
- PMG Research
-
Winston-Salem, North Carolina, Stati Uniti, 27157
- Reclutamento
- Wake Forest Baptist Health
-
Contatto:
- Bob Hmieleski
- Numero di telefono: 336-713-8550
- Email: bhmieles@wakehealth.edu
-
Investigatore principale:
- Andrew Namen, MD
-
-
Ohio
-
Cincinnati, Ohio, Stati Uniti, 45267
- Attivo, non reclutante
- University of Cincinnati Medical Center
-
Cleveland, Ohio, Stati Uniti, 44195
- Reclutamento
- Cleveland Clinic
-
Investigatore principale:
- Brian Southern, MD
-
Contatto:
- Ron Wehrmann
- Numero di telefono: 2164450574
- Email: wehrmar@ccf.org
-
Columbus, Ohio, Stati Uniti, 43210
- Reclutamento
- The Ohio State University
-
Contatto:
- Benjamin Hood
- Email: benjamin.hood2@osumc.edu
-
Investigatore principale:
- John Odackal
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Stati Uniti, 73104
- Reclutamento
- University of Oklahoma
-
Investigatore principale:
- Jad Kebbe, MD
-
Contatto:
- Maria Mason
- Numero di telefono: 405-271-6173
- Email: maria-l-mason@ouhsc.edu
-
-
Oregon
-
Portland, Oregon, Stati Uniti, 97220
- Reclutamento
- Oregon Clinic
-
Investigatore principale:
- David Hotchkin, MD
-
Contatto:
- Meg Day
- Numero di telefono: 503-963-3182
- Email: mday@orclinic.com
-
-
Pennsylvania
-
Hershey, Pennsylvania, Stati Uniti, 17033
- Reclutamento
- Penn State College of Medicine - Hershey
-
Investigatore principale:
- Rebecca Bascom, MD
-
Contatto:
- Tim Sheehan
- Numero di telefono: 717-531-2925
- Email: tsheehan@pennstatehealth.psu.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19140
- Reclutamento
- Temple University
-
Investigatore principale:
- Rachel Criner, MD
-
Contatto:
- Luis Cardenas-Osorio
- Numero di telefono: 215-707-3311
- Email: Luis.Cardenas-Osorio@tuhs.temple.edu
-
Philadelphia, Pennsylvania, Stati Uniti, 19144
- Reclutamento
- Thomas Jefferson University
-
Investigatore principale:
- Ross Summer, MD
-
Contatto:
- Ramya Talluri, BSN, RN
- Email: RamyaPriya.Talluri@jefferson.edu
-
-
South Carolina
-
Charleston, South Carolina, Stati Uniti, 29425
- Reclutamento
- Medical University of South Carolina
-
Investigatore principale:
- Timothy Whelan, MD
-
Contatto:
- Audra Wiser
- Email: wisera@musc.edu
-
-
Tennessee
-
Nashville, Tennessee, Stati Uniti, 37232
- Reclutamento
- Vanderbilt University
-
Contatto:
- James Del Greco
- Numero di telefono: 615-343-7068
- Email: james.del.greco@vumc.org
-
Investigatore principale:
- Justin Hewlett, MD
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75235
- Reclutamento
- University of Texas Southwestern
-
Investigatore principale:
- John Fitzgerald, MD
-
Contatto:
- Meagan Galvan
- Numero di telefono: 214-645-6489
- Email: Maegan.Galvan@UTSouthwestern.edu
-
Dallas, Texas, Stati Uniti, 75246
- Reclutamento
- Baylor University Medical Center at Dallas
-
Investigatore principale:
- Yolanda Mageto, MD
-
Contatto:
- Mary Alayo
- Numero di telefono: 214-820-6276
- Email: Mary.Alayo@BSWHealth.org
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Baylor College of Medicine
-
Investigatore principale:
- Ivan Rosas, MD
-
Contatto:
- Maria C Perea
- Email: Maria.Perea@bcm.edu
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- Houston Methodist Lung Center
-
Investigatore principale:
- Zeenat Safdar, MD
-
Contatto:
- Laura Valecillos Loukidis
- Numero di telefono: 346-238-4637
- Email: lvvalecillosloukidis@houstonmethodist.org
-
Houston, Texas, Stati Uniti, 77030
- Reclutamento
- The University of Texas Health Science Center At Houston
-
Investigatore principale:
- Rodeo Abrencillo, MD
-
Contatto:
- Beverly Rios
- Numero di telefono: 713-486-6152
- Email: Beverly.Rios@uth.tmc.edu
-
-
Utah
-
Salt Lake City, Utah, Stati Uniti, 84108
- Reclutamento
- University of Utah
-
Contatto:
- Adeline Langer
- Numero di telefono: 801-581-5811
- Email: adeline.langer@hsc.utah.edu
-
Investigatore principale:
- Mary Beth Langer, MD
-
Salt Lake City, Utah, Stati Uniti, 84111
- Reclutamento
- Intermountain Health
-
Contatto:
- Aisha Skowyra
- Numero di telefono: 801-507-2439
- Email: Aisha.fairclough@imail.org
-
Investigatore principale:
- Erin Blackstock, MD
-
-
Vermont
-
Colchester, Vermont, Stati Uniti, 05446
- Attivo, non reclutante
- University of Vermont Lung Center
-
-
Virginia
-
Charlottesville, Virginia, Stati Uniti, 22908
- Attivo, non reclutante
- University from Virginia
-
Falls Church, Virginia, Stati Uniti, 22042-3307
- Reclutamento
- Inova Health Care Services
-
Contatto:
- Taruni Maganti
- Numero di telefono: 703-776-3230
- Email: Taruni.Maganti@inova.org
-
Investigatore principale:
- Jared Wilkinson, MD
-
-
Wisconsin
-
Milwaukee, Wisconsin, Stati Uniti, 53226
- Attivo, non reclutante
- The Medical College of Wisconsin
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.
Descrizione
Inclusion Criteria:
-
Willing and able to provide informed consent
-
Established a new diagnosis (within 12 months) of IPF by the enrolling center.
-
Age 21 years or older, or
-
Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:
-
Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.
-
Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):
- decline in FVC % predicted (% pred) based on ≥10% relative decline
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
- decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
- decline in DLCO % pred based on≥ 10% relative decline
- worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.
-
The relative decline for FVC % predicted is calculated using the formula:
Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.
The relative decline for DLCO % predicted is calculated using the formula:
Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening
Exclusion Criteria:
- Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
- Currently listed for lung transplantation at the time of enrollment
- Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
- For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Coorti e interventi
Gruppo / Coorte |
|---|
|
Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry |
|
Subjects with a non-IPF ILD diagnosis
Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype |
|
New Subjects with a new IPF diagnosis
Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Data on natural history of IPF & non-IPF chronic fibrosing ILD
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD |
End of Study (3 years after last patient will be enrolled)
|
|
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL). |
End of Study (3 years after last patient will be enrolled)
|
|
Blood samples for future research.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions. |
End of Study (3 years after last patient will be enrolled)
|
|
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Collect longitudinal HRCT images for future research |
End of Study (3 years after last patient will be enrolled)
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Data on management practices compared to existing guidelines.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Compare disease-specific management practices with existing guidelines. |
End of Study (3 years after last patient will be enrolled)
|
|
Data on center-specific practices on outcomes.
Lasso di tempo: End of Study (3 years after last patient will be enrolled)
|
Determine the influence of center-specific practices on patient outcomes. |
End of Study (3 years after last patient will be enrolled)
|
Collaboratori e investigatori
Sponsor
Collaboratori
Investigatori
- Investigatore principale: Scott Palmer, MD, Duke Clinical Research Institute, Duke University
Pubblicazioni e link utili
Pubblicazioni generali
- Swaminathan AC, Hellkamp AS, Neely ML, Bender S, Paoletti L, White ES, Palmer SM, Whelan TPM, Dilling DF; Idiopathic Pulmonary Fibrosis Prospective Outcomes Registry investigators. Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis: An Analysis of the IPF-PRO Registry. Ann Am Thorac Soc. 2022 Jun;19(6):981-990. doi: 10.1513/AnnalsATS.202105-589OC.
- Kim HJ, Snyder LD, Neely ML, Hellkamp AS, Hotchkin DL, Morrison LD, Bender S, Leonard TB, Culver DA; IPF-PRO Registry investigators. Clinical Outcomes of Patients with Combined Idiopathic Pulmonary Fibrosis and Emphysema in the IPF-PRO Registry. Lung. 2022 Feb;200(1):21-29. doi: 10.1007/s00408-021-00506-x. Epub 2022 Jan 7.
- de Andrade JA, Kulkarni T, Neely ML, Hellkamp AS, Case AH, Culver DA, Guntupalli K, Bender S, Conoscenti CS, Snyder LD; IPF-PRO Registry Investigators. Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2022 Jan 7;23(1):3. doi: 10.1186/s12931-021-01921-7.
- Kim HJ, Snyder LD, Adegunsoye A, Neely ML, Bender S, White ES, Conoscenti CS, Strek ME; IPF-PRO Registry Investigators. Hospitalizations in patients with idiopathic pulmonary fibrosis. Respir Res. 2021 Sep 30;22(1):257. doi: 10.1186/s12931-021-01851-4.
- Salisbury ML, Conoscenti CS, Culver DA, Yow E, Neely ML, Bender S, Hartmann N, Palmer SM, Leonard TB; IPF-PRO Registry principal investigators as follows. Antifibrotic Drug Use in Patients with Idiopathic Pulmonary Fibrosis. Data from the IPF-PRO Registry. Ann Am Thorac Soc. 2020 Nov;17(11):1413-1423. doi: 10.1513/AnnalsATS.201912-880OC.
- Fan Y, Bender SD, Conoscenti CS, Davidson-Ray L, Cowper PA, Palmer SM, de Andrade JA; IPF-PRO Registry Investigators. Hospital-Based Resource Use and Costs Among Patients With Idiopathic Pulmonary Fibrosis Enrolled in the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Chest. 2020 Jun;157(6):1522-1530. doi: 10.1016/j.chest.2019.12.041. Epub 2020 Jan 29.
- O'Brien EC, Hellkamp AS, Neely ML, Swaminathan A, Bender S, Snyder LD, Culver DA, Conoscenti CS, Todd JL, Palmer SM, Leonard TB; IPF-PRO Registry investigators. Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry. Chest. 2020 May;157(5):1188-1198. doi: 10.1016/j.chest.2019.11.042. Epub 2020 Jan 15.
- Todd JL, Neely ML, Overton R, Durham K, Gulati M, Huang H, Roman J, Newby LK, Flaherty KR, Vinisko R, Liu Y, Roy J, Schmid R, Strobel B, Hesslinger C, Leonard TB, Noth I, Belperio JA, Palmer SM; IPF-PRO Registry investigators. Peripheral blood proteomic profiling of idiopathic pulmonary fibrosis biomarkers in the multicentre IPF-PRO Registry. Respir Res. 2019 Oct 22;20(1):227. doi: 10.1186/s12931-019-1190-z.
- Snyder L, Neely ML, Hellkamp AS, O'Brien E, de Andrade J, Conoscenti CS, Leonard T, Bender S, Gulati M, Culver DA, Kaner RJ, Palmer S, Kim HJ; IPF-PRO Registry investigators. Predictors of death or lung transplant after a diagnosis of idiopathic pulmonary fibrosis: insights from the IPF-PRO Registry. Respir Res. 2019 May 30;20(1):105. doi: 10.1186/s12931-019-1043-9.
- O'Brien EC, Durheim MT, Gamerman V, Garfinkel S, Anstrom KJ, Palmer SM, Conoscenti CS. Rationale for and design of the Idiopathic Pulmonary Fibrosis-PRospective Outcomes (IPF-PRO) registry. BMJ Open Respir Res. 2016 Jan 11;3(1):e000108. doi: 10.1136/bmjresp-2015-000108. eCollection 2016.
- Swaminathan AC, Weber JM, Todd JL, Palmer SM, Neely ML, Whelan TP, Kim GHJ, Leonard TB, Goldin J. Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28;26(1):73. doi: 10.1186/s12931-025-03136-6.
- Oldham JM, Neely ML, Wojdyla DM, Gulati M, Li P, Patel DC, Palmer SM, Todd JL; IPF-PRO Registry Investigators. Changes in Lung Function and Mortality Risk in Patients With Idiopathic Pulmonary Fibrosis. Chest. 2025 Aug;168(2):415-422. doi: 10.1016/j.chest.2025.02.018. Epub 2025 Feb 26.
- Sack C, Wojdyla DM, MacMurdo MG, Gassett A, Kaufman JD, Raghu G, Redlich CA, Li P, Olson AL, Leonard TB, Todd JL, Neely ML, Snyder LD, Gulati M; IPF-PRO Registry investigators. Long-Term Air Pollution Exposure and Severity of Idiopathic Pulmonary Fibrosis: Data from the Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry. Ann Am Thorac Soc. 2025 Mar;22(3):378-386. doi: 10.1513/AnnalsATS.202404-382OC.
- Wang L, Wu P, Liu Y, Patel DC, Leonard TB, Zhao H. Clustering-aided prediction of outcomes in patients with idiopathic pulmonary fibrosis. Respir Res. 2024 Oct 23;25(1):383. doi: 10.1186/s12931-024-03015-6.
- Lobo LJ, Liu Y, Li P, Ramaswamy M, Swaminathan AC, Veeraraghavan S, Fan Y, Neely ML, Palmer SM, Olson AL; ILD-PRO Registry investigatorsdagger. Design and baseline characteristics of the ILD-PRO registry in patients with progressive pulmonary fibrosis. BMC Pulm Med. 2024 Sep 27;24(1):468. doi: 10.1186/s12890-024-03247-8.
- Summer R, Todd JL, Neely ML, Lobo LJ, Namen A, Newby LK, Shafazand S, Suliman S, Hesslinger C, Keller S, Leonard TB, Palmer SM, Ilkayeva O, Muehlbauer MJ, Newgard CB, Roman J. Circulating metabolic profile in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Respir Res. 2024 Jan 25;25(1):58. doi: 10.1186/s12931-023-02644-7.
- Neely ML, Hellkamp AS, Bender S, Todd JL, Liesching T, Luckhardt TR, Oldham JM, Raj R, White ES, Palmer SM. Lung function trajectories in patients with idiopathic pulmonary fibrosis. Respir Res. 2023 Aug 24;24(1):209. doi: 10.1186/s12931-023-02503-5.
- Ruan P, Todd JL, Zhao H, Liu Y, Vinisko R, Soellner JF, Schmid R, Kaner RJ, Luckhardt TR, Neely ML, Noth I, Porteous M, Raj R, Safdar Z, Strek ME, Hesslinger C, Palmer SM, Leonard TB, Salisbury ML. Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression. Respir Res. 2023 May 31;24(1):141. doi: 10.1186/s12931-023-02435-0.
- Menon AA, Gansen B, Mulder H, Neely ML, Papavasileiou P, Salisbury ML, Southern BD, Hesslinger C, Leonard TB, Meissner F, Todd JL. Mass spectrometry-based peripheral blood proteomics for biomarker discovery in idiopathic pulmonary fibrosis. Respir Res. 2025 Oct 22;26(1):294. doi: 10.1186/s12931-025-03377-5.
- Shetty S, Swaminathan AC, Li P, Neely ML, Olson AL, Snyder LD; ILD-PRO Registry investigators. Workplace Productivity Loss in Patients with Progressive Pulmonary Fibrosis: Data from the ILD-PRO Registry. Lung. 2026 May 27;204(1):32. doi: 10.1007/s00408-026-00895-x.
- Swaminathan AC, Mulder H, Neely ML, Schmid R, Belperio JA, Patel NM, Palmer SM, Todd JL. Expression of complement pathway genes is associated with progression of idiopathic pulmonary fibrosis. Respir Res. 2026 Mar 25;27(1):196. doi: 10.1186/s12931-026-03641-2.
- Neely ML, Todd JL, Snyder LD, Li P, Olson AL; IPF-PRO Registry Investigators *. Trajectories of Health-Related Quality of Life in Patients With Idiopathic Pulmonary Fibrosis. CHEST Pulm. 2024 Dec 27;3(4):100133. doi: 10.1016/j.chpulm.2024.100133. eCollection 2025 Dec.
- MacMurdo MG, Wojdyla DM, Gassett A, Kaufman JD, Raghu G, Redlich CA, Patel DC, Neely ML, Snyder LD, Gulati M, Sack C; IPF-PRO Registry investigators. Short-term air pollution exposure and hospitalizations in idiopathic pulmonary fibrosis: data from the IPF-PRO Registry. Ann Am Thorac Soc. 2026 Sep 12:aaoag285. doi: 10.1093/annalsats/aaoag285. Online ahead of print.
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stimato)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- Pro00046131
- 1199.174 (Altro identificatore: DCRI)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .